Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. adult patients (18 years or older), both sexes~2. Sars-CoV-2 infection confirmed by PCR less than 4 days before randomization~3. hospitalized with a diagnosis of SARS-CoV-2 pneumonia~4. radiographic evidence of pulmonary infiltrates~5. grade 4 or 5 on the ordinal scale for the evaluation of the patient's clinical condition~6. pO2/FiO2 \<380~7. men and women of childbearing age who have heterosexual relations must be agreement to use the safe method(s) of contraception~8. obtaining the informed consent of the patient or the legal representative.~Exclusion Criteria:~1. imminent death (life expectancy less than 72h)~2. known hypersensitivity or known adverse reactions to the study drug, or its metabolites or excipients of the formulation~3. invasive mechanical ventilation~4. participation in any other clinical trial~5. ALT or AST \> 5 x ULN~6. creatinine clearance \<50 mL/min using the Cockcroft-Gault formula for participants '18 years old \[Cockcroft 1976\]~7. patients with recent acute coronary syndrome (\<1 month)~8. patients with a history of stroke~9. positive pregnancy test~10. pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (SoC) (Type: ACTIVE_COMPARATOR): None
- SoC + Icatibant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).